ライフサイエンスコーパス: hepatocellular cancer

1 most common primary hepatic malignancy after hepatocellular cancer.

2 ll cycle progression, and ultimately lead to hepatocellular cancer.

3 iated thyroid cancer compared with renal and hepatocellular cancer.

4 ir potential therapeutic application against hepatocellular cancer.

5 mpared with sorafenib experience in renal or hepatocellular cancer.

6 gase complex, is overexpressed in breast and hepatocellular cancers.

7 nic liver failure (4 patients), and solitary hepatocellular cancer (1 patient) were the main indicati

8 HE (7 patients) and hepatocellular cancer (2 patients) were confounding diag

9 he HCV cohort (P = 0.03), including incident hepatocellular cancer (6 versus 18; P = 0.03), but that

10 (UNOS) status of recipient, and presence of hepatocellular cancer affected the outcome of OLT.

11 For recurrence of hepatocellular cancer after hepatic resection or local a

12 gression to advanced disease, cirrhosis, and hepatocellular cancer and are more likely to develop liv

13 oplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.

14 fy TICs of various tumor entities, including hepatocellular cancer and glioblastoma.

15 Aflatoxin promotes hepatocellular cancer, and fumonisin may promote esophag

16 with advanced renal-cell carcinoma (RCC) or hepatocellular cancer, and its application in other type

17 atic tumors such as hepatocellular adenomas, hepatocellular cancers, and hepatoblastomas have mutatio

18 curs during liver growth in hepatoblastomas, hepatocellular cancers, and liver regeneration.

19 vidence of elevated frequency in bladder and hepatocellular cancer cells.

20 Hepatocellular cancer deaths were positively related to

21 sociated with faster entry into S phase, and hepatocellular cancer formation.

22 ue-specific gastrointestinal cancers such as hepatocellular cancers, gastric adenocarcinomas, and col

23 associated with survival after recurrence of hepatocellular cancer (HCC) after resection and the outc

24 BACKGROUND AND AIMS: The risk of hepatocellular cancer (HCC) after sustained virological

25 DD45beta has been verified to be specific in hepatocellular cancer (HCC) and consistent with the p53

26 ) exception points provided to patients with hepatocellular cancer (HCC) are not based on outcome dat

27 Hepatoblastoma (HBL) and hepatocellular cancer (HCC) are the most common primary

28 e evaluated the expression of miRNA in human hepatocellular cancer (HCC) by expression profiling, and

29 xpression was markedly reduced in four human hepatocellular cancer (HCC) cell lines compared with nor

30 dergoing liver transplantation for stage 1-2 hepatocellular cancer (HCC) have an excellent long-term

31 Hepatocellular cancer (HCC) is an established indication

32 Hepatocellular cancer (HCC) is the fifth most common sol

33 y in vivo, in HLA-A*0201+AFP+ advanced stage hepatocellular cancer (HCC) patients, and have activated

34 Examination of human hepatocellular cancer (HCC) reveals cells that label wit

35 ut the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplant

36 atively available variables in patients with hepatocellular cancer (HCC) waiting for liver transplant

37 t 40% of elf(+/-) mice spontaneously develop hepatocellular cancer (HCC) with markedly increased cycl

38 fide tumor suppressor, is down-regulated in hepatocellular cancer (HCC).

39 tions in DNA methylation frequently occur in hepatocellular cancer (HCC).

40 pathway is implicated in the pathogenesis of hepatocellular cancer (HCC).

41 expression of ultraconserved RNAs (ucRNA) in hepatocellular cancer (HCC).

42 patitis (NASH) may progress to cirrhosis and hepatocellular cancer (HCC).

43 FRalpha) signaling is evident in a subset of hepatocellular cancers (HCCs).

44 however, is observed in a subset of primary hepatocellular cancers (HCCs).

45 and ligand expression is frequently seen in hepatocellular cancers (HCCs).

46 sessed in mice bearing human PlGF-expressing hepatocellular cancer (Huh7) xenografts or human renal c

47 to link tamoxifen with an increased rate of hepatocellular cancer in humans; the contrasting carcino

48 The recent increase in the incidence of hepatocellular cancer in the United States is thought to

49 status was not independently associated with hepatocellular cancer (IRR = 0.96; 95% CI, 0.56 to 1.63)

50 Hepatocellular cancer is a highly vascular tumor, where

51 Screening for hepatocellular cancer is justified.

52 Hepatocellular cancer is notorious for recurrence even a

53 V1-TK has been demonstrated in the livers of hepatocellular cancer patients.

54 However, many details about hepatocellular cancer stem cells that are important for

55 e for the TGF-beta signaling pathway in both hepatocellular cancer suppression and endoderm formation

56 wer rates of liver-related complications and hepatocellular cancer than corresponding patients with H

57 e beta-catenin), regenerating livers, and in hepatocellular cancer tissues that exhibit beta-catenin

58 eiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0.60; 95% CI: 0.28-1.28, p =

59 is also associated with an increased risk of hepatocellular cancer, which may occur even in the absen